EMA Authorised: Emend (aprepitant) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Emend (aprepitant) by Merck Sharp & Dohme B.V. for prevention of vomiting and nausea in cancer patients, including postoperative nausea and v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Postoperative Nausea and Vomiting

Drugs mentioned

• EMEND (aprepitant)

Snippet

Status: Authorised. Therapeutic area: Vomiting;Postoperative Nausea and Vomiting;Cancer. MAH: Merck Sharp & Dohme B.V.. Decision date: 24/10/2025